<DOC>
	<DOCNO>NCT00475878</DOCNO>
	<brief_summary>This study design test whether treatment depressive symptom use escitalopram improves adherence Buprenorphine reduce symptom depression individual receive Buprenorphine medical provider .</brief_summary>
	<brief_title>SSRI Buprenorphine</brief_title>
	<detailed_description>Participants interested receive Buprenorphine offer opportunity enroll study . Enrolled study participant complete interview baseline every two week total 8 interview 3 month . In double-blind randomized control trial , participant either receive placebo escitalopram ( 10mg ) . All participant also follow Buprenorphine clinic medical provider . Questions face-to-face interview assess mood , drug craving , pain , sleep , medication adherence drug-related experience . Comparison ( ) : Participants randomize medication component study compare participant randomize placebo component study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>opiate dependence HamD &gt; 14 psychiatric contraindication use escitalopram medical contraindication use escitalopram methadone dose &lt; 30 current SSRI use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>opiate use</keyword>
	<keyword>depression</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>escitalopram</keyword>
</DOC>